Wyeth-Ayerst's Cordarone (amiodarone I.V.)
Executive Summary
New formulation of the inotropic agent will be reviewed by FDA's Cardiovascular & Renal Drugs Advisory Committee on Oct. 14. The American Home Products unit filed the NDA for the new dosage form (20-377) in January 1993. On Oct. 13, the committee will discuss drug interactions and anti-anginal guidelines. The meeting begins at 9 a.m. both days in Masur Auditorium on the NIH campus